All In Biotech

Drug Trial Radar · NCT07463040

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

A Multi-Arm, Multi-Stage Randomized Controlled Clinical Trial Evaluating Systemic Therapeutic Regimens for the Treatment of Cutaneous Leishmaniasis in Ethiopia

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Mar 1, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
London School of Hygiene and Tropical Medicine; Uppsala University; University of Stellenbosch; Armauer Hansen Research Institute, Ethiopia; Wollo University; Arba Minch University
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system. The multi-centre multi-arm multi-stage phase 3 clinical trial is designed to rigorously evaluate a total of 4 alternative treatment options for systemic CL against Sodium Stibugluconate (SSG) as the standard of care. The trial comprises two seamlessly linked stages. In stage 1, all four investigational arms will be evaluated against the control arm for efficacy to inform the selection of the arms, based on a pre-defined efficacy threshold that will advance to stage 2, in addition to the control arm. After stage 2, the experimental interventions will be compared with SSG similar to a standard superiority trial for efficacy. The general study design in stage 1 and stage 2 will be identical; only the number of investigational arms may differ. Patients will be randomized into the respective treatment arms at the recruitment sites of Arba Minch hospital, Boru Meda hospital and ALERT hospital in Ethiopia. Individuals will be hospitalized during the entire course of their treatment. As different arms have different treatment duration, patient hospitalization period and visit schedules will differ between arms. In total, the study will last 180 days for each participant.

Conditions

  • Cutaneous Leihmaniasis

Interventions

  • Sodium Stibogluconate (SSG)Drug

    Intramuscular Administration - once daily for 28 days

  • MiltefosineDrug

    Miltefosine - Oral Administration, daily for 28 days

  • Miltefosine + ParomomycinDrug

    Miltefosine - Oral Administration, daily for 28 days + Paromomycine - Intramuscular Administration, once daily for 14 days

  • Liposomal Amphotericin B (LAmB)Drug

    Intravenous Administration, once daily on days 1, 3, 5, 7, 10, 12, 14, 17, 19, 21

  • Pentamidine isethionateDrug

    Intravenous Administration - once daily on days 1, 3, 5, 7, 9, 11, 13

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For each of the investigational arms (miltefosine/miltefosine + paromomycin / liposomal amphotericin B/pentamidine isethionate), to determine whether it has superior efficacy to the control arm in terms of achieving cure of all lesions at Day 90Time frame: Day 90

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • ALERT Hospital

    Addis Ababa, Ethiopia

  • Arba Minch General Hospital

    Arba Minch, Ethiopia

  • Boru Meda General Hospital

    Boru, Ethiopia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.